CART-EGFRvIII T cells

BIOLOGICAL2 trials

Sponsors

University of Pennsylvania

Conditions

GlioblastomaPatients With Residual or Reccurent EGFRvIII+ Glioma

Phase 1

Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma

TerminatedNCT02209376

University of PennsylvaniaPatients With Residual or Reccurent EGFRvIII+ Glioma

Start: 2014-11-18End: 2018-04-04Updated: 2023-06-22

CART-EGFRvIII + Pembrolizumab in GBM

CompletedNCT03726515

University of PennsylvaniaGlioblastoma

Start: 2019-03-11End: 2021-02-27Updated: 2023-06-22

Related Papers

Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial.

2024-01-12113 citations

CTIM-24. REPEATED PERIPHERAL INFUSIONS OF ANTI-EGFRVIII CAR T CELLS IN COMBINATION WITH PEMBROLIZUMAB REMODELS THE TUMOR MICROENVIRONMENT IN DE NOVO GLIOBLASTOMA

Neuro-Oncology2023-11-014 citations

PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response

Frontiers in Immunology2022-05-0630 citations

IMMU-16. CHARACTERISTICS OF EGFRVIII-DIRECTED CART CELL INFUSION PRODUCT ASSOCIATED WITH CLINICAL RESPONSE IN RECURRENT GLIOBLASTOMA

Neuro-Oncology2021-11-02

High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms

Frontiers in Oncology2021-09-1035 citations

Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma

Frontiers in Oncology2021-05-0769 citations

IMMU-36. HIGH AFFINITY CHIMERIC ANTIGEN RECEPTOR WITH CROSS-REACTIVITY TO CLINICALLY-RELEVANT EGFR MUTATED PROTEINS

Neuro-Oncology2020-11-01

RBTT-12. A PHASE I STUDY OF EGFRVIII-DIRECTED CAR T CELLS COMBINED WITH PD-1 INHIBITION IN PATIENTS WITH NEWLY, DIAGNOSED, MGMT-UNMETHYLATED GLIOBLASTOMA: TRIAL IN PROGRESS

Neuro-Oncology2019-11-019 citations

Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas

Molecular Therapy — Oncolytics2018-08-28175 citations

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma

OncoImmunology2018-02-01100 citations

Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma.

Journal of Clinical Oncology2016-05-2031 citations

Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma.

PubMed2016-01-0113 citations

Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

Science Translational Medicine2015-02-18448 citations